Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|18|2876-2882

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.18, 2014-09, pp. : 2876-2882

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multi-Parametric Magnetic Resonance Imaging to Rule-In and Rule-Out Clinically Important Prostate Cancer in Men at Risk: A Cohort Study

By  

Urologia Internationalis, Vol. 87, Iss. 1, 2011-06 ,pp. : 49-53

Karger

Access to resources Recommend Favorite

In‐parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 527-534

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Use of the Finasteride-Adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican Referral Population: A Validation Study

By  

Urologia Internationalis, Vol. 89, Iss. 1, 2012-05 ,pp. : 9-16

Karger

Access to resources Recommend Favorite

Multiparametric magnetic resonance imaging identifies significant apical prostate cancers

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 239-243

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate‐specific antigen and biopsy outcome

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3007-3011

John Wiley & Sons Inc

Access to resources Recommend Favorite